Parainfluenza virus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A systematic review

Shah, Dimpy P.; Shah, Pankil; Azzi, Jacques; Chemaly, Roy F.

doi:10.1016/j.canlet.2015.11.014

Cited by 86 publications

(115 citation statements)

References 56 publications

Supporting

Mentioning

111

Contrasting

Order By: Relevance

“…Parainfluenza virus (PIV) is a respiratory virus commonly detected after hematopoietic cell transplantation (HCT) [1–3]. Human PIV has four subtypes, numbered 1 through 4 [4, 5].…”

Section: Introductionmentioning

confidence: 99%

“…PIV type 3 (PIV-3) is the most common subtype and a frequent cause of outbreaks among HCT recipients [6–8]. PIV can progress from upper respiratory tract infection (URTI) to lower respiratory tract disease (LRTD), resulting in mortality as high as 40–50% [3, 9–11]. Identification of risk factors for progression to LRTD and their relative importance is critical in clinical practice and designing clinical trials of novel drugs and immunotherapies.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Risk Factors for Parainfluenza Virus Lower Respiratory Tract Disease after Hematopoietic Cell Transplantation

Seo

Xie

Leisenring

et al. 2019

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

Parainfluenza virus (PIV) infection can progress from upper respiratory tract infection (URTI) to lower respiratory tract disease (LRTD) in immunocompromised hosts. Risk factors for progression to LRTD and presentation with LRTD without prior URTI are poorly defined. Hematopoietic cell transplant (HCT) recipients with PIV infection were retrospectively analyzed using standardized definitions of LRTD. PIV was detected in 540 HCT recipients; 343 had URTI alone and 197 (36%) had LRTD (possible, 76; probable, 19; proven, 102). Among 476 patients with positive nasopharyngeal samples, the cumulative incidence of progression to probable/proven LRTD by day 40 was 12%, with a median time to progression of 7 days (range, 2 to 40). In multivariable analysis monocytopenia (hazard ratio, 2.22; P = .011), steroid use ≥1mg/kg prior to diagnosis (hazard ratio, 1.89; P = .018), co-pathogen detection in blood (hazard ratio, 3.21; P = .027), and PIV type 3 (hazard ratio, 3.57; P = .032) were associated with increased progression risk. In the absence of all 4 risk factors no patients progressed to LRTD, whereas progression risk increased to>30% if 3 or more risk factors were present. Viral load or ribavirin use appeared to have no effect on progression. Among 121 patients with probable/proven LRTD, 64 (53%) presented LRTD without prior URTI, and decreased lung function before infection and lower respiratory co-pathogens were risk factors for this presentation. Mortality was unaffected by the absence of prior URTI. We conclude that the risk of progression to probable/proven LRTD exceeded 30% with ≥3 risk factors. To detect all cases of LRTD, virologic testing of lower respiratory samples is required regardless of URTI symptoms.

show abstract

“…Parainfluenza virus (PIV) is a respiratory virus commonly detected after hematopoietic cell transplantation (HCT) [1–3]. Human PIV has four subtypes, numbered 1 through 4 [4, 5].…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Risk Factors for Parainfluenza Virus Lower Respiratory Tract Disease after Hematopoietic Cell Transplantation

Seo

Xie

Leisenring

et al. 2019

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

show abstract

“…Hospital-acquired viral infections are a particular problem in pediatric settings, with upwards of one-third of HAIs attributable to viruses (2). Hospital acquisition of human parainfluenza viruses (HPIVs) has been recognized as a particular problem among patients with cancer, including pediatric patients (3). In one study, 80% of HPIV infections in pediatric cancer patients were acquired in the hospital (4).…”

Section: Introductionmentioning

confidence: 99%

Rapid Metagenomic Next-Generation Sequencing during an Investigation of Hospital-Acquired Human Parainfluenza Virus 3 Infections

et al. 2017

View full text Add to dashboard Cite

Metagenomic next-generation sequencing (mNGS) is increasingly used for the unbiased detection of viruses, bacteria, fungi, and eukaryotic parasites in clinical samples. Whole-genome sequencing (WGS) of clinical bacterial isolates has been shown to inform hospital infection prevention practices, but this technology has not been utilized during potential respiratory virus outbreaks. Here, we report on the use of mNGS to inform the real-time infection prevention response to a cluster of hospital-acquired human parainfluenza 3 virus (HPIV3) infections at a children's hospital. Samples from 3 patients with hospital-acquired HPIV3 identified over a 12-day period on a general medical unit and 10 temporally associated samples from patients with community-acquired HPIV3 were analyzed. Our sample-to-sequencer time was <24 h, while our sample-to-answer turnaround time was <60 h with a hands-on time of approximately 6 h. Eight (2 cases and 6 controls) of 13 samples had sufficient sequencing coverage to yield the whole genome for HPIV3, while 10 (2 cases and 8 controls) of 13 samples gave partial genomes and all 13 samples had >1 read for HPIV3. Phylogenetic clustering revealed the presence of identical HPIV3 genomic sequence in the two of the cases with hospital-acquired infection, consistent with the concern for recent transmission within the medical unit. Adequate sequence coverage was not recovered for the third case. This work demonstrates the promise of mNGS for providing rapid information for infection prevention in addition to microbial detection.

show abstract

“…There are increasing numbers of patients undergoing HSCT with increasing complexity. However, there also are newer drugs being studied for the treatment of viral infections (i.e., adenovirus, parainfluneza virus, and respiratory syncytial virus) in this population and they offer a potential to suppress or eliminate these viruses throughout the peri-transplant continuum [16][17][18]. Further prospective studies will be needed to determine the clinical impact and optimal prevention and treatment strategies for RVI's in this population.…”

Section: Discussionmentioning

confidence: 99%

Respiratory Viral Detection in the Pediatric Hematopoietic Stem Cell Transplant Population

Shapiro¹,

Lopez-Marti²,

Woods³

et al. 2017

Pediatric Infect Dis

View full text Add to dashboard Cite

Respiratory viral infections (RVI) are a frequent cause of morbidity and mortality in hematopoietic stem cell transplant (HSCT) patients. We examined clinical characteristics and respiratory viral detection in asymptomatic pediatric HSCT pre-transplant patients and symptomatic post-transplant patients. Coxsackie/echovirus (most common virus detected pre and post-transplant), rhinovirus, and coronavirus were detected pre-transplant and at the first post-transplant event suggesting persistent detection. None of the clinical characteristics examined were associated with viral detection and there was no increase in mortality noted with asymptomatic viral detection.

show abstract

Parainfluenza virus infections in hematopoietic cell transplant recipients and hematologic malignancy patients: A systematic review

Cited by 86 publications

References 56 publications

Risk Factors for Parainfluenza Virus Lower Respiratory Tract Disease after Hematopoietic Cell Transplantation

Risk Factors for Parainfluenza Virus Lower Respiratory Tract Disease after Hematopoietic Cell Transplantation

Rapid Metagenomic Next-Generation Sequencing during an Investigation of Hospital-Acquired Human Parainfluenza Virus 3 Infections

Respiratory Viral Detection in the Pediatric Hematopoietic Stem Cell Transplant Population

Contact Info

Product

Resources

About